Vnitr Lek 2018, 64(3):266-271 | DOI: 10.36290/vnl.2018.037

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Štefan Alušík1,*, Zoltán Paluch2
1 Department of Internal Medicine, Institute for Postgraduate Medical Education, Prague
2 Department of Pharmacology, Charles University Medical School 2, Prague

Non-steroidal anti-inflammatory drugs (NSAIDs) belong to the most widely used drugs. Results of recent large meta-analyses have shown that the cardiovascular risk of NSAIDs is more serious than originally believed and is not associated exclusively with coxibs; it is also increased when using so called traditional NSAIDs. Data obtained to date show the safest drugs of this class in terms of cardiovascular risk are naproxen and ibuprofen at low doses. The position of naproxen as the safest NSAID has been challenged by some more recent findings. The authors examine some results of meta-analyses and conclusions of regulatory agencies.

Keywords: cardiovascular risk; coxibs; diclofenac; ibuprofen; naproxen; non-steroidal anti-inflammatory drugs

Received: August 18, 2017; Accepted: October 9, 2017; Published: March 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Alušík Š, Paluch Z. Cardiovascular risk of non-steroidal anti-inflammatory drugs. Vnitr Lek. 2018;64(3):266-271. doi: 10.36290/vnl.2018.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Toone EC Jr, Irby WR. Evaluation of phenylbutazone (Butazolidin) in the treatment of rheumatoid spondylitis: Report of 50 cases. Ann Intern Med 1954; 41(1): 70-78. Go to original source... Go to PubMed...
    2. Kuzell WC, Schaffarzick RW, Brown B et al. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc 1952; 149(8): 729-734. Go to original source... Go to PubMed...
    3. Hakkarainen TW, Steele SR, Bastaworous A et al. Nonsteroidal anti-inflammatory drugs and the risk for anastomotic failure: a report from Washington State's Surgical Care and Outcomes Assessment Program (SCOAP). JAMA Surg 2015; 150(3): 223-228. Dostupné z DOI: <http://dx.doi.org/10.1001/jamasurg.2014.2239>. Erratum in Incorrect table title. [JAMA Surg. 2015]. Go to original source... Go to PubMed...
    4. Sherif BQ, Al-Zohyri AM, Shibab SS. Effects of Some Non Steroidal Anti-inflammatory Drugs on Ovulation in Women with Mild Musculoskeletal Pain (A Clinical Study). IOSR-JPBS 2014; 9(4): 43-49. Dostupné z WWW: <http://iosrjournals.org/iosr-jpbs/papers/Vol9-issue4/Version-4/G09444349.pdf>. Go to original source...
    5. European Medicines Agency: New safety advice for diclofenac. Dostupné z WWW: <http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diclofenac-containing_medicinal_products/European_Commission_final_decision/WC500155819.pdf>.
    6. [U.S. Food and Drug Administration]. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Dostupné z WWW: <https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm>.
    7. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382(9894): 769-779. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(13)60900-9>. Go to original source... Go to PubMed...
    8. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.c7086>. Go to original source... Go to PubMed...
    9. Schjerning Olsen AM, Fosbol E, Lindhardsen J et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123(20): 2226-2235. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.004671>. Go to original source... Go to PubMed...
    10. Schjerning Olsen AM, Gislason GH, McGettigan P et al. Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction. JAMA 2015; 313(8): 805-814. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.0809>. Go to original source... Go to PubMed...
    11. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 2011; 8(9): e1001098. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pmed.1001098>. Go to original source... Go to PubMed...
    12. Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013; 22(6): 559-570. Dostupné z DOI: <http://dx.doi.org/10.1002/pds.3437>. Go to original source... Go to PubMed...
    13. Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 2008; 10(11): 1102-1107. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejheart.2008.07.013>. Go to original source... Go to PubMed...
    14. Liu G, Yan YP, Zheng XX et al. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol 2014; 114(10): 1523-1529. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2014.08.015>. Go to original source... Go to PubMed...
    15. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302-1308. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.332.7553.1302>. Go to original source... Go to PubMed...
    16. MacDonald T, Hawkey C, Ford I et al. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur Heart J 2017; 38(23): 1843-1850. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehw387>. Erratum in Corrigendum [Eur Heart J 2016]. Go to original source... Go to PubMed...
    17. Grigoriou A, Ibrahim F, Chaabo K et al. Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data. Rheumatology 2016; 55(4): 763-764. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kev386>. Go to original source... Go to PubMed...
    18. Gnjidic D, Blyth FM, Le Couteur DG et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) in older people: Prescribing patterns according to pain prevalence and adherence to clinical guidelines. Pain 2014; 155(9): 1814-1820. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pain.2014.06.009>. Go to original source... Go to PubMed...
    19. da Costa, BR, Reichenbach, S, Keller, N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016;387(10033):2093-2105. Retraction in: Lancet 2017; 390(10090): 109. Corrected and republished in: Lancet 2017; 390(10090): e21-e33. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(17)31744-0>. Go to original source... Go to PubMed...
    20. Moore RA, Moore N. Paracetamol and pain: the kiloton problem. Eur J Hosp Pharm 2016; 23: 187-188. Dostupné z DOI: <http://dx.doi.org/10.1136/ejhpharm-2016-000952>. Go to original source... Go to PubMed...
    21. Voloshyna I, Kasselman LJ, Carsons SE et al. COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. J Investig Med 2017; 65(3): 694-704. Dostupné z DOI: <http://dx.doi.org/10.1136/jim-2016-000259>. Go to original source... Go to PubMed...
    22. Stitham J, Hwa J. Prostacyclin, atherothrombosis and diabetes mellitus: Physiologic and clinical considerations. Curr Mol Med 2016; 16(4): 328-342. Go to original source... Go to PubMed...
    23. Ahmetaj-Shala B, Kirkby NS, Knowles R et al. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation 2015; 131(7): 633-642. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011591>. Go to original source... Go to PubMed...
    24. Kirkby NS, Lundberg MH, Wright WR et al. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: Identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One 2014; 9(6): e98165. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0098165>. Go to original source... Go to PubMed...
    25. Ghosh R, Hwang SM, Cui Z et al. Different effects of the nonsteroidal anti-inflammatory drugs meclofenamate sodium and naproxen sodium on proteasome activity in cardiac cells. J Mol Cell Cardiol 2016; 94: 131-34. Dostupné z DOI: <http://dx.doi.org/10.1016/j.yjmcc.2016.03.016>. Go to original source... Go to PubMed...
    26. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52(20): 1628-1636. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.08.041>. Go to original source... Go to PubMed...
    27. Nissen SE, Yeomans ND, Solomon DH et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375(26): 2519-2529. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611593>. Go to original source... Go to PubMed...
    28. Bello A, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Clinical implications. Drug Saf 2014; 37(11): 897-902. Dostupné z DOI: <http://dx.doi.org/10.1007/s40264-014-0207-2>. Go to original source... Go to PubMed...
    29. FitzGerald GA. Imprecision: Limitations to interpretation of a large randomized clinical trial. Circulation 2017; 135(2): 113-115. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026324>. Go to original source... Go to PubMed...
    30. Gunter BR, Butler KA, Wallace RL et al. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse event: a meta-analysis. J Clin Pharm Ther 2017; 42(1): 27-38. Dostupné z DOI: <http://dx.doi.org/10.1111/jcpt.12484>. Go to original source... Go to PubMed...
    31. Wen IC, Hsiao FY, Chan KA et al. Acute respiratory infection and use of non-steroidal anti-inflammatory drugs on risk of acute myocardial infarction: A nation-wide case-crossover study. J Infect Dis 2017; 215(4): 503-509. Dostupné z DOI: <http://dx.doi.org/10.1093/infdis/jiw603>. Go to original source... Go to PubMed...
    32. Zingler G, Hermann B, Fischer T et al. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risk. Expert Rev Clin Pharmacol 2016; 9(11): 1479-1492. Dostupné z DOI: <http://dx.doi.org/10.1080/17512433.2016.1230495>. Go to original source... Go to PubMed...
    33. Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017; 357: j1909. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.j1909>. Go to original source... Go to PubMed...
    34. Quan M. Hot Topics in Primary Care: The Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs: Putting the Evidence in Perspective. J Fam Practice 2017; 66(4 Suppl): S52-S57.
    35. Ruoff G Hot topics in Primary Care: Nonsteroidal anti-inflammatory drugs and cardiovascular risk: Where are we today? J Fam Pract 2015; 64(12 Suppl): S67-S70.
    36. [No authors listed]. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac. Prescrire Int 2016; 25(167): 14-16. Go to PubMed...
    37. Thomas D, Ali Z, Zachariah S et al. Coxibs refocus attention on the cardiovascular risk of non-aspirin NSAIDs. Am J Cardiovasc Drugs 2017; 17(5): 343-346. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256-017-0223-6>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.